ReviewCurrent issues in molecular biology2026
Diabetes and Cancer-Pathophysiology and Clinical Implications: A Systematic Review.
Review in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes Mellitus and cancer are major global health problems with rising incidence worldwide. This systematic review was conducted following PRISMA 2020 guidelines by searching PubMed, Scopus, ScienceDirect, SpringerLink, and Google Scholar for studies published between 2015 and 2026. Studies investigating the association between diabetes mellitus and cancer were selected based on predefined criteria, and data were synthesized using a narrative approach. The findings indicate a strong and mechanistically complex association between diabetes mellitus and multiple cancers, particularly pancreatic, breast, colorectal, and prostate cancers. Hyperglycemia, insulin resistance, and chronic inflammation are consistently implicated in tumor initiation and progression through key signaling pathways, including Wnt/β-catenin, PI3K/AKT/mTOR, and AMPK. A bidirectional relationship is most evident in pancreatic cancer, highlighting its unique metabolic and oncogenic interplay. Shared molecular mediators such as cytokines, microRNAs, and metabolic regulators further support a common pathogenic link. Metformin, an antidiabetic drug, demonstrated potential anticancer effects via modulation of these interconnected pathways. Overall, this review underscores a biologically intertwined relationship between diabetes mellitus and cancer, supporting the development of integrated therapeutic strategies targeting shared metabolic and signaling mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.